Drugs / Fisogatinib
Fisogatinib
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT02508467 | Jul 2015 → Jun 2021 | hepatocellular carcinoma | Blueprint Medicines Corporation | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT04194801 | Dec 2019 → Oct 2021 | hepatocellular carcinoma | CStone Pharmaceuticals | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Fisogatinib | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02508467 ↗ |
| Known as | BLU-111362 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4514636 ↗ |
| Known as | BLU-554 | “Phase Ib: participants received 400 mg Fisogatinib (BLU-554) once daily (QD), in combination with 1200mg fixed dose Sugemalimab (CS1001) once every 3 weeks (Q3W).” NCT04194801 ↗ |
| Known as | X-439161 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4514636 ↗ |
| Modality | Small molecule | — CHEMBL4514636 ↗ |
| Route | Oral | “administered orally” NCT02508467 ↗ |